Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | LTA4H | P09960 | 1/20 | 0.49 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14421921 | 0.88 | TDP1 (0.56) | SMN1; SMN2KDM4ETDP1HTTTSHR | |
| SCHEMBL171015 | 0.87 | NPC1 (0.65) | SMN1; SMN2KDM4EHTTTSHRMEN1 | |
| SCHEMBL171148 | 0.87 | SMN1; SMN2 (0.46) | SMN1; SMN2KDM4ETDP1HTTTSHR | |
| SCHEMBL13648209 | 0.87 | TDP1 (0.52) | SMN1; SMN2KDM4ETDP1HTTTSHR | |
| SCHEMBL165581 | 0.83 | KDM4E (0.53) | SMN1; SMN2KDM4ETDP1HTTTSHR | |
| SCHEMBL13648169 | 0.81 | ALDH1A1 (0.58) | SMN1; SMN2KDM4ETDP1HTTTSHR | |
| SCHEMBL14970479 | 0.79 | SMN1; SMN2 (0.74) | SMN1; SMN2KDM4ETDP1HTTTSHR | |
| SCHEMBL12726118 | 0.77 | SMN1; SMN2 (0.71) | SMN1; SMN2KDM4ETDP1HTTTSHR | |
| SCHEMBL13861966 | 0.77 | SMN1; SMN2 (0.67) | SMN1; SMN2KDM4ETDP1HTTTSHR | |
| SCHEMBL14453571 | 0.76 | SMN1; SMN2 (0.97) | SMN1; SMN2KDM4ETDP1HTTTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130158076-A1 | Methylene Urea Derivatives | MERCK PATENT GMBH (DE) | 2013-06-20 | — | — | US | disclosed |
| US-20130158076-A1 | Methylene Urea Derivatives | MERCK PATENT GMBH (DE) | 2013-06-20 | — | — | US | disclosed |
| US-8410143-B2 | Methylene urea derivatives | MERCK PATENT GMBH (DE) | 2013-04-02 | — | — | US | disclosed |
| US-8410143-B2 | Methylene urea derivatives | MERCK PATENT GMBH (DE) | 2013-04-02 | — | — | US | disclosed |
| EP-2426122-A1 | Methylene urea derivative as RAF kinasse inhibitors | Merck Patent GmbH (DE) | 2012-03-07 | — | — | EP | disclosed |
| US-20090298885-A1 | METHYLENE UREA DERIVATIVES | MERCK PATENT GMBH (DE) | 2009-12-03 | — | — | US | disclosed |
| US-20090298885-A1 | METHYLENE UREA DERIVATIVES | MERCK PATENT GMBH (DE) | 2009-12-03 | — | — | US | disclosed |
| US-20090253688-A1 | Semicarbazide derivatives as kinase inhibitors | MERCK PATENT GMBH (DE) | 2009-10-08 | — | — | US | disclosed |
| US-20090253688-A1 | Semicarbazide derivatives as kinase inhibitors | MERCK PATENT GMBH (DE) | 2009-10-08 | — | — | US | disclosed |
| US-7589112-B2 | Methylene urea derivatives | MERCK PATENT GMBH (DE) | 2009-09-15 | — | — | US | disclosed |
| US-20070191423-A1 | Isoquinoline derivatives | MERCK PATENT GMBH (DE) | 2007-08-16 | — | — | US | disclosed |
| US-20070191423-A1 | Isoquinoline derivatives | MERCK PATENT GMBH (DE) | 2007-08-16 | — | — | US | disclosed |
| US-20070191444-A1 | Benzimidazolyl derivatives | MERCK PATENT GMBH (DE) | 2007-08-16 | — | — | US | disclosed |
| US-20070191444-A1 | Benzimidazolyl derivatives | MERCK PATENT GMBH (DE) | 2007-08-16 | — | — | US | disclosed |
| US-20070161677-A1 | Bisarylurea derivatives | MERCK PATENT GMBH (DE) | 2007-07-12 | — | — | US | disclosed |
| US-20070161677-A1 | Bisarylurea derivatives | MERCK PATENT GMBH (DE) | 2007-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191444-A1 | Benzimidazolyl derivatives | JAK1, MARK1, RAF1 | SMN1; SMN2 2417/4885KDM4E 1022/4885TDP1 1372/4885 |
| US-20070161677-A1 | Bisarylurea derivatives | BRAF, RAF1, NRAS | SMN1; SMN2 4056/4885KDM4E 2459/4885TDP1 835/4885 |
| US-20090298885-A1 | METHYLENE UREA DERIVATIVES | BRAF, RAF1, CMPK1 | SMN1; SMN2 2976/4885KDM4E 480/4885TDP1 2246/4885 |
| US-20070191423-A1 | Isoquinoline derivatives | ABL1, MAP3K1, MAP3K2 | SMN1; SMN2 2588/4885KDM4E 1691/4885TDP1 1060/4885 |
| US-20130158076-A1 | Methylene Urea Derivatives | BRAF, RAF1, CMPK1 | SMN1; SMN2 2976/4885KDM4E 480/4885TDP1 2246/4885 |
| US-20090253688-A1 | Semicarbazide derivatives as kinase inhibitors | MAP3K1, MAP3K6, MAP3K2 | SMN1; SMN2 3294/4885KDM4E 1349/4885TDP1 2019/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.